Effect of drug substrates on the reduction of hepatic microsomal cytochrome P-450 by NADPH.

@article{Gigon1968EffectOD,
  title={Effect of drug substrates on the reduction of hepatic microsomal cytochrome P-450 by NADPH.},
  author={Philippe Gigon and Theodore E. Gram and James R. Gillette},
  journal={Biochemical and biophysical research communications},
  year={1968},
  volume={31 4},
  pages={
          558-62
        }
}
Binding of a Cyano- and Fluoro-containing Drug Bicalutamide to Cytochrome P450 46A1
TLDR
The x-ray structures of P450 46A1 were determined in complex with the R and S isomers of the anticancer drug bicalutamide and it was observed that access to the P450 active site was affected by differential recognition of S versus R isomers at the CYP46A1 surface arising from BIC conformational polymorphism.
Bicalutamide-CYP 46 A 1 interactions 1 Binding of a Cyano-and Fluoro-Containing Drug Bicalutamide to Cytochrome P 450 46 A 1 : Unusual Features and Spectral Response *
TLDR
It is demonstrated how conformational polymorphism affects drug entry and binding in the P450 active site through the cyano group of the folded bicalutamide conformer via a water molecule.
Stimulation of cerebral cholesterol turnover 1 Pharmacologic stimulation of cytochrome P 450 46 A 1 and cerebral cholesterol turnover in mice
TLDR
CYP46A1 could be a novel therapeutic target and a tool to further investigate the physiological and medical significance of cerebral cholesterol turnover, and efavirenz may be devoid of adverse effects elicited by high drug concentrations.
Apocytochrome P-450: Reconstitution of
TLDR
Findings indicate that phenobarbital-mediated induction of apocytochrome P-450 is independent of heme, and it is suggested that synthesis of the apocy tochrome may be the primary and rate-limiting event in the forma- tion of cytochromeP-450.
Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy
TLDR
The results enhance the potential of CYP27A1 as an antibreast cancer target, could be of importance for the interpretation of Femara versus Anastrozole Clinical Evaluation Trial, and bring attention to posaconazole as a potential complementary anti-breast cancer medication.
Inhibition and stimulation of activity of purified recombinant CYP11A1 by therapeutic agents
Pharmacologic Stimulation of Cytochrome P450 46A1 and Cerebral Cholesterol Turnover in Mice*
TLDR
CYP46A1 could be a novel therapeutic target and a tool to further investigate the physiological and medical significance of cerebral cholesterol turnover to lead to new therapeutic strategies for the treatment of brain disorders.
Hepatic and Extrahepatic Mixed-Function Oxidases
TLDR
The sections in this article are: types of Mixed-Function Oxidase Reactions, Characteristics of Microsomal Electron Transport Chain, and Hormonal Regulation of Hepatic and Extrahepatic Mixed- Function Oxidases in Human Beings.
...
...

References

SHOWING 1-3 OF 3 REFERENCES
Photochemical Action Spectrum of the Terminal Oxidase of Mixed Function Oxidase Systems
TLDR
The agreement between photochemical action spectrum and spectrophotometric difference spectrum supports the conclusion that the CO-binding pigment is the terminal oxidase of mixed function oxidase systems of mammals.